D&D Pharmatech FAP contrast agent Phase 2launches; SD Biosensor targets public TB procurement

D&D Pharmatech’s global technology-transfer partner began 2026year 7month 8day clinical 2phase for a candidate FAP-targeted contrast agent. Clinical 2phase is the stage at which efficacy and safety are confirmed more fully, making it a watershed for the future regulatory approval and commercialization schedule.

D&D Pharmatech said on the same day that the candidate targets FAP (fibroblast activation protein). The company disclosed that the clinical trial had begun.

SD Biosensor announced on 2026year 7month 8day that it would make a full-scale push into the global public procurement market with tuberculosis diagnostic products. The company said it aims to enter overseas procurement markets and expand orders through public procurement.

Hanwha Aerospace 2026year 7month 8day announced that it would participate in the North Atlantic Treaty Organization (NATO) defense industry forum and pursue expanded cooperation. The company disclosed that it discussed areas of cooperation through its participation in the forum.

Seoul Mayor Oh Se-hoon 2026year 7month 8day said it was the starting point for elevating Seoul, a good city in which to raise children, to a global top3. On the same day, Kang Won-rae shared an update on his pressure sore treatment and said he was currently undergoing treatment, including disinfection.

The companies concerned 2026year 7month 8day disclosed the relevant information, and further disclosures are expected regarding clinical progress, public procurement contracts, and cooperation related to the forum.